The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Northern District of California on behalf of investors who purchased Thoratec Corporation (“Thoratec” or the “Company”) (NasdaqGS:THOR) securities between April 29, 2010 and November 27, 2013.
Click here to learn about the case: http://docs.wongesq.com/THOR-Info-Request-Form-192. There is no cost or obligation to you.
The complaint alleges that the Company made materially false and/or misleading statements and omitted materially adverse facts regarding the Company’s business, operations, and prospects. In particular, it is alleged that the Company failed to disclose that its HeartMate II Left Ventricular Assist Device held significant risk of pump thrombosis, causing numerous fatalities.
On April 4, 2012, a recall was issued on the Company’s HeartMate II heart pumps over concern for a potentially deadly defect. On November 27, 2013, The New England Journal of Medicine released a study concluding that the “rate of pump thrombosis related to the use of the HeartMate II has been increasing at our centers and is associated with substantial morbidity and mortality.”If you suffered a loss in Thoratec you have until March 25, 2014 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email firstname.lastname@example.org, by telephone at 212.425.1140, or visit http://docs.wongesq.com/THOR-Info-Request-Form-192. Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts